A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer Se Hoon ParkEunmi NamJae Hoon Lee Original Article 10 August 2007 Pages: 1 - 9
Sequential vinorelbine–capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial Marwan GhosnJoseph KattanFor the Cancer Research Group/Collaborative Group (CRG/CG), Beirut–Lebanon Original Article 24 August 2007 Pages: 11 - 18
Preclinical studies of treosulfan demonstrate potent activity in Ewing’s sarcoma Sebastian WernerArnulfo MendozaUdo Kontny Original Article 01 September 2007 Pages: 19 - 31
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis Richard M. LoganRachel J. GibsonDorothy M. K. Keefe Original Article 17 August 2007 Pages: 33 - 41
Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer Nanae TomonagaYoichi Nakamurathe Nagasaki Thoracic Oncology Group Original Article 24 August 2007 Pages: 43 - 49
In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines Judith A. SmithAnjali GaikwadClinton F. Stewart Original Article 12 September 2007 Pages: 51 - 58
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein–Barr virus DNA as a biomarker of efficacy Brigette MaEdwin P. HuiAnthony T. C. Chan Original Article 29 August 2007 Pages: 59 - 64
Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia Peter D. ColeRichard A. DrachtmanBarton A. Kamen Original Article 02 September 2007 Pages: 65 - 75
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma Jeeyun LeeYoung-Hyuck ImYoung Mog Shim Original Article 31 August 2007 Pages: 77 - 84
Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity Vincenzo GuarcelloCarmelo BlanquicettMahmoud H. el Kouni Original Article 01 September 2007 Pages: 85 - 96
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety Feng GuoStephen P. LetrentAmarnath Sharma Original Article 06 September 2007 Pages: 97 - 109
Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells Tadahiko KuboShoji ShimoseMitsuo Ochi Original Article 15 September 2007 Pages: 111 - 116
Mechanistic study of potentiation of chemotherapy by a haloenol lactone derivative in vitro Wei WangCindy Q. XiaJiang Zheng Original Article 25 September 2007 Pages: 117 - 122
Pharmacodynamic model for chemotherapy-induced anemia in rats Sukyung WooWojciech KrzyzanskiWilliam J. Jusko Original Article 22 September 2007 Pages: 123 - 133
Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment Gerald J. FetterlyJoel S. OwenJuan Jose Perez-Ruixo Original Article 09 October 2007 Pages: 135 - 147
Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer Howard H. BaileySteven AttiaJames A. Stewart Original Article 21 September 2007 Pages: 149 - 157
Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer Tomo OsakoYoshinori ItoKiyohiko Hatake Original Article 20 September 2007 Pages: 159 - 164
Bisphosphonates induce apoptosis in CLL cells independently of MDR phenotype Karina Lani SilvaDeborah Vidal VasconcellosRaquel Ciuvalschi Maia Original Article 12 March 2008 Pages: 165 - 171
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer J. HortiE. JuhaszI. Bodrogi Clinical Trial Report 23 January 2008 Pages: 173 - 180
Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome C. S. Chim Letter to the Editor 31 August 2007 Pages: 181 - 182